Patricia D. Jones

University of Miami Miller School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Supplementary Table 4 shows the results from the adjusted multivariable logistic regression analyses evaluating for predictors of delays in HCC treatment (≥3 months vs.

Year:

2025

Supplementary figure 1A shows the overall 5-year survival of patients with HCC stratified by age groups. Supplementary figure 1B shows the overall 5-year survival of patients with HCC stratified by sex. Supplementary figure 1C shows the overall 5-year survival of patients with HCC stratified by race/ethnicity. Supplementary figure 1D shows the overall 5-year survival of patients with HCC stratified by geography. Supplementary figure 1E shows the overall 5-year survival of patients with HCC stratified by annual household income.

Year:

2025

Supplementary Table 1 shows the results of adjusted multivariable logistic regression analyses evaluating for predictors of tumor stage at diagnosis among patients with HCC, stratified by race/ethnicity.

Year:

2025

Background: Hepatocellular carcinoma (HCC) disproportionately affects racial/ethnic minorities. We evaluated the impact of income and geography on racial/ethnic disparities across the HCC care cascade in the United States. Methods: Using NCI registry data spanning 2000 to 2020, adults with HCC were evaluated to determine race/ethnicity-specific differences in tumor stage at diagnosis, delays and gaps in treatment, and survival. Adjusted regression models evaluated predictors of HCC outcomes. Results: Among 112,389 adults with HCC, cohort characteristics were as follows: 49.8% non-Hispanic White (NHW), 12.0% African American(AA), 20.5% Hispanic, 16.5% Asian/Pacific Islander, and 1.1% American Indian/Alaska Native. Compared with NHW patients, AA patients had lower odds of localized-stage HCC at diagnosis [adjusted odds ratio (aOR), 0.84], lower odds of HCC treatment receipt (aOR, 0.77), greater odds of treatment delays (aOR, 1.12), and significantly greater risk of death [adjusted hazards ratio (aHR), 1.10]. Compared with NHW patients from large metro areas, AA patients from large metro areas had 8% higher mortality risk (aHR, 1.08), whereas AA patients from small–medium metro areas had 17% higher mortality risk (aHR, 1.17; all P Conclusions: Among a population-based cohort of US adults with HCC, significant race/ethnicity-specific disparities across the HCC care continuum were observed. Lower household income and more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients. Impact: Our study shows that lower income and less urban/more rural geography among racial/ethnic minorities are also associated with disparities in HCC outcomes, particularly among AA patients with HCC. This contextualizes the complex relationship between sociodemographic factors and HCC outcomes through an intersectional lens.

Year:

2025

Introduction: Hepatitis delta virus (HDV) increases risk of cirrhosis and hepatocellular carcinoma in patients with hepatitis B, however HDV screening rates are low. We assessed providers’ perceived barriers to HDV screening and management. Methods: We distributed an Internet-based survey to members of three Gastroenterology/Hepatology organizations. Results: Most respondents, 69.3% correctly identified the appropriate HDV screening test. Several reported barriers to HDV care, including uncertainty of screening criteria, 55.5%, and lack of treatment knowledge, 66.7%. Discussion: Our findings highlight the need for increased education regarding HDV care. Education should be combined with standardized approaches that increase ease of HDV screening.

Year:

2024

Background: Previous survival studies on hepatocellular carcinoma (HCC) by etiology are limited to hospital-based series, restricted cohorts, and monolithic etiologic categories. We studied population-based survival by seven mutually exclusive HCC etiologic groups—standalone hepatitis-C virus (HCV), hepatitis-B virus (HBV), alcohol-related liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), and dual etiology HCV–HBV, HCV–ALD, and HBV–ALD—accounting for clinical and sociodemographic characteristics. Methods: All HCC cases diagnosed during 2005 to 2018 from the Florida Cancer Registry were linked for etiology using statewide discharge and viral hepatitis data. We performed a cause-specific survival analysis including Cox regression for the matched 15,616 cases by HCC etiology. Results: The leading etiology was HCV only ( n = 4,983; 31.9%); the leading dual etiology was HCV–ALD ( n = 2,552; 16.3%). The five-year adjusted survival was low—17.6% overall and Conclusions: ALD only and dual etiologies involving ALD show worse prognosis for HCC compared with viral etiology alone. To increase survival, improved screening and treatment are needed for patients with multiple HCC risk factors. Impact: Understanding US disparities in HCC survival by etiology can help guide the identification of etiologically specific biomarkers and potential therapeutic targets and inform public health measures.

Year:

2024

5. Supplementary Table S5 shows age-adjusted 5-year HCC-specific survival by single etiology or select dual etiology groups, a sensitivity analysis for all HCC cases and for complete HCC cases.

Year:

2024

4. Supplementary Table S4 shows multivariable Cox proportional hazards regression models in which HCC-specific survival is assessed based on period of diagnosis, prior or during 2013 and after 2013, for HCV only cases and for non-HCV related cases.

Year:

2024

1. Supplementary Table S1 shows International Classification of Diseases discharge codes used to define the following hepatocellular carcinoma etiologies: chronic hepatitis C virus infection, chronic hepatitis B virus infection, alcohol-related liver conditions, metabolic/non-alcoholic fatty liver disease-related conditions, biliary conditions, autoimmune conditions, and genetic conditions.

Year:

2024

3. Supplementary Table S3 shows a multivariable Cox proportional hazards regression model in which HCC-specific survival is assessed based on cigarette smoking status, with the reference population of past smokers.

Year:

2024

Collaborators (7)

Robert J. Wong

Stanford University School of Medicine

UNITED STATES
View details

Amit G. Singal

-

UNITED STATES
View details

Isildinha Reis

Research Professor

University of Miami Health System

UNITED STATES
View details

Wei Zhang

Transplant hepatologist/Assistant professor

Massachusetts General Hospital

UNITED STATES
View details

Erin N. Kobetz

University of Miami Miller School of Medicine

UNITED STATES
View details

Mandana Khalili

Professor of Medicine

University of California, San Francisco

UNITED STATES
View details

Paulo S. Pinheiro

University of Miami Miller School of Medicine

UNITED STATES
View details